In a historic move, Dr. Mansukh Mandaviya unveiled the National Policy on Research and Development and Innovation in the Pharma-MedTech Sector (PRIP). The launch event, attended by prominent figures such as Dr. V. K. Paul, Member of NITI Aayog, Ms. S Aparna, Secretary (Pharma), Ministry of Chemicals and Fertilizers, and Dr. Rajiv Bahl, Director General of ICMR, marked a significant milestone in India’s pursuit of self-reliance and innovation in the pharmaceutical and medical technology industries.
Transforming the Pharma-MedTech Sector
Dr. Mandaviya emphasized the need to transform India’s pharmaceutical and medical technology sectors from being cost-based to value-based and innovation-driven. The PRIP scheme focuses on creating an ecosystem that fosters skills and capacities, involving academia and the private sector while encouraging youth entrepreneurship through start-ups.
He highlighted the importance of synergy between various government institutions and agencies, including the Pharma Department, ICMR, DST, DBT, and NIPER, in achieving these goals. Dr. Mandaviya reiterated India’s commitment to growth and innovation, citing the successful response to the COVID-19 pandemic as an example of the country’s resilience.
Bulk Drug and Medical Device Parks
To strengthen the pharmaceutical and medical device sectors, India has established three bulk drug parks in Himachal Pradesh, Vizag, and Gujarat, along with four medical device parks in Himachal Pradesh, Uttar Pradesh, Madhya Pradesh, and Tamil Nadu. These initiatives aim to promote self-reliance and reduce dependency on foreign sources for critical medical supplies.
Dr. Mandaviya stressed that self-reliance in pharmaceuticals and medical devices can only be achieved through robust research and development infrastructure. He emphasized the importance of collaboration between industries, academia, and policymakers to align research and innovation with the country’s needs and global demands.
Dr. V. K. Paul, Member (Health) of NITI Aayog, emphasized that India is leading the world in healthcare and pharmaceutical reforms. He highlighted the significance of collaboration between academia, public, and private institutions in preparing for future challenges and ensuring national biosecurity.
The launch of the National Policy on Research and Development and Innovation in the Pharma-MedTech Sector reflects India’s commitment to becoming a global hub for pharmaceuticals and medical exports, driven by research, innovation, and self-reliance. The policy is expected to have far-reaching implications for the country’s healthcare and pharmaceutical sector, positioning it as a key player on the global stage.